Skip to content

Anastim in management of Hairloss

ANASTIM study: ANastim (Neoruscine, Tocopherol nicotinate, GP4G and Biotin) Assessment of Safety and Tolerability In Management of Hairloss

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/06/005873
Enrollment
150
Registered
2015-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hair Loss patients

Interventions

Intervention1: Anastim (Neuroruscin, Tocopherol nicotinate , GP4G and Biotin): Anastim to be applied once daily three times a week in the evening 2.5 ml to dry or wet hair, massage gently for 2 mont

Sponsors

Abbott Healthcare Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy male and female subjects who are 18 to 40 years of age. 2.Patients with hair loss disorders such as telogen effluvium (as first line therapy), chronic female pattern hair loss, Androgenetic Alopecia (Stage I â?? IV) (as combination with minoxidil) 3.Site involved - scalp

Exclusion criteria

Exclusion criteria: 1.Androgenetic alopecia (Stage V and beyond) 2.Evidence of dermatological disease as revealed by history, physical examination or laboratory assessment which may interfere with administration or assessment of study medication 3.Current use of dermatological drugs / preparations which may interfere with study evaluation 4.Intolerance to any of ingredients of the formulation 5.Current alcohol or drug abuse 6.Subjects viewed by the investigator as not being able to complete the study. 7.Hair product such as hair dyes, sprays, setting gels and restorers 8.Any procedures for hair enhancement and curling or straightening techniques 9.Pregnant or breastfeeding women 10.Patient or having participated in a clinical trial in the month before

Design outcomes

Primary

MeasureTime frame
â?¢Improvement in hair growth by clinical digital photography Timepoint: Baseline & 8 weeks

Secondary

MeasureTime frame
â?¢Percentage of patients responding to the therapy â?¢Hair Pull test (or additional Hair Shedding test) â?¢Adverse event assessment â?¢Acceptability of the treatment â?¢Tolerance of the treatment â?¢Global assessment for efficacy by Investigator and Patient â?¢Global assessment for tolerability by Investigator and Patient Timepoint: Baseline & 8 weeks

Countries

India

Contacts

Public ContactManoj Prabhu

Abbott Healthcare Pvt Ltd

manoj.naik@abbott.in022-39536910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026